Allergan scrubs some doc-payment data, spares med-ed grants

Share this article:

Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011. What's left are listings of payments made to physicians in the third quarter of 2011, as well as medical education grants dating back to late 2010.

Unlike the payment data that were removed, the remaining listings classify the healthcare provider payment into one of several categories such as educational materials, business travel or meals. However, the earlier listings showed not just ranges but specific dollar amounts.

“The earlier reports were accurate but simply removed from Allergan's Web site because they would not provide meaningful or accurate comparisons on Allergan's healthcare provider payments relative to the more comprehensive report currently available,” Heather Katt, an Allergan spokeswoman, told MM&M by e-mail.

The disappearing data were first reported by, and some of the information can still be viewed on its Dollars for Docs database, specifically reports covering the last half of 2010.

Later this month, Allergan plans on adding two new reports to its site showing HCP spend for the last half of 2011, as per a corporate integrity agreement the company signed with the Office of Inspector General of the US Department of Health and Human Services that went into effect in August 2010. That year Allergan agreed to plead guilty and pay $600 million to resolve criminal and civil liability arising from promotion of Botox for unapproved uses.

Medical-education grant listings for the first six months of 2011, and from September to December 2010, are still viewable on Allergan's website. The corporate integrity agreement requires the company to post the med-ed records bi-annually.

"We will post a new [med-ed] report at the end of this month for the period of July 1- December 31, 2011," Katt noted. "The report currently on the site will remain. The format and data categories in the report that will be posted at the end of the month are the same as the report currently posted."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...